Overview

24-hour Efficacy and Ocular Surface With Talfuprost and Triple Combined Therapy

Status:
Completed
Trial end date:
2016-01-01
Target enrollment:
Participant gender:
Summary
The study investigated the 24-hour efficacy and ocular surface health with preservative-free tafluprost and a combined preservative-free regimen (tafluprost and dorzolamide/timolol fixed combination) in open-angle glaucoma patients insufficiently controlled on latanoprost monotherapy and showing signs, or symptoms of ocular surface disease with preservative-containing latanoprost monotherapy. This trial randomized open-angle glaucoma patients insufficiently controlled (IOP > 20 mm Hg) on branded, or generic latanoprost monotherapy who required further IOP reduction and who demonstrated clinical signs, or symptoms of ocular surface disease.
Phase:
Phase 4
Details
Lead Sponsor:
Aristotle University Of Thessaloniki
Treatments:
Dorzolamide
Timolol